Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

Core Viewpoint - Intellia Therapeutics is set to hold an investor webcast on October 24, 2024, to discuss Phase 2 data for its gene editing therapy NTLA-2002, which aims to treat hereditary angioedema (HAE) [1][2]. Group 1: Company Overview - Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on CRISPR-based therapies, with programs designed for precise editing of disease-causing genes both in vivo and ex vivo [5]. - The company has developed NTLA-2002, which is based on CRISPR/Cas9 technology and aims to be the first one-time treatment for hereditary angioedema by inactivating the KLKB1 gene [3]. Group 2: Product Information - NTLA-2002 has shown promising interim Phase 1 clinical data, demonstrating significant reductions in attack rates and consistent decreases in kallikrein levels [3]. - The therapy has received multiple regulatory designations, including Orphan Drug and RMAT Designation from the U.S. FDA, Innovation Passport from the U.K. MHRA, and PRIME Designation from the European Medicines Agency [3]. Group 3: Industry Context - Hereditary angioedema is a rare genetic disease affecting approximately 1 in 50,000 people, characterized by severe and unpredictable inflammatory attacks [4]. - Current treatment options for HAE often require lifelong therapies, which may involve chronic administration and still result in breakthrough attacks, highlighting the need for innovative solutions like NTLA-2002 [4].